Literature DB >> 8732755

Structural investigation of the alpha-1-antichymotrypsin: prostate-specific antigen complex by comparative model building.

B O Villoutreix1, H Lilja, K Pettersson, T Lövgren, O Teleman.   

Abstract

Prostate-specific antigen (PSA), produced by prostate cells, provides an excellent serum marker for prostate cancer. It belongs to the human kallikrein family of enzymes, a second prostate-derived member of which is human glandular kallikrein-1 (hK2). Active PSA and hK2 are both 237-residue kallikrein-like proteases, based on sequence homology. An hK2 model structure based on the serine protease fold is presented and compared to PSA and six other serine proteases in order to analyze in depth the role of the surface-accessible loops surrounding the active site. The results show that PSA and hK2 share extensive structural similarity and that most amino acid replacements are centered on the loops surrounding the active site. Furthermore, the electrostatic potential surfaces are very similar for PSA and hK2. PSA interacts with at least two serine protease inhibitors (serpins): alpha-1-antichymotrypsin (ACT) and protein C inhibitor (PCI). Three-dimensional model structures of the uncleaved ACT molecule were developed based upon the recent X-ray structure of uncleaved antithrombin. The serpin was docked both to PSA and hK2. Amino acid replacements and electrostatic complementarities indicate that the overall orientation of the proteins in these complexes is reasonable. In order to investigate PSA's heparin interaction sites, electrostatic computations were carried out on PSA, hK2, protein C, ACT, and PCI. Two heparin binding sites are suggested on the PSA surface and could explain the enhanced complex formation between PSA and PCI, while inhibiting the formation of the ACT-PSA complex, PSA, hK2, and their preliminary complexes with ACT should facilitate the understanding and prediction of structural and functional properties for these important proteins also with respect to prostate diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8732755      PMCID: PMC2143410          DOI: 10.1002/pro.5560050505

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  71 in total

1.  Modeling of prostate specific antigen and human glandular kallikrein structures.

Authors:  M Vihinen
Journal:  Biochem Biophys Res Commun       Date:  1994-11-15       Impact factor: 3.575

2.  Substrate specificity of tissue kallikreins: importance of an extended interaction site.

Authors:  M Brillard-Bourdet; T Moreau; F Gauthier
Journal:  Biochim Biophys Acta       Date:  1995-01-05

3.  Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop.

Authors:  A Wei; H Rubin; B S Cooperman; D W Christianson
Journal:  Nat Struct Biol       Date:  1994-04

4.  Role of the H helix in heparin binding to protein C inhibitor.

Authors:  R A Shirk; M G Elisen; J C Meijers; F C Church
Journal:  J Biol Chem       Date:  1994-11-18       Impact factor: 5.157

5.  Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard.

Authors:  A Bélanger; H van Halbeek; H C Graves; K Grandbois; T A Stamey; L Huang; I Poppe; F Labrie
Journal:  Prostate       Date:  1995-10       Impact factor: 4.104

6.  Production of recombinant PSA and HK2 and analysis of their immunologic cross-reactivity.

Authors:  J Lövgren; T Piironen; C Overmo; B Dowell; M Karp; K Pettersson; H Lilja; A Lundwall
Journal:  Biochem Biophys Res Commun       Date:  1995-08-24       Impact factor: 3.575

7.  Identification of thrombin residues that modulate its interactions with antithrombin III and alpha 1-antitrypsin.

Authors:  B F Le Bonniec; E R Guinto; S R Stone
Journal:  Biochemistry       Date:  1995-09-26       Impact factor: 3.162

8.  Structure of the Ca(2+)-free Gla domain sheds light on membrane binding of blood coagulation proteins.

Authors:  M Sunnerhagen; S Forsén; A M Hoffrén; T Drakenberg; O Teleman; J Stenflo
Journal:  Nat Struct Biol       Date:  1995-06

9.  The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions.

Authors:  H A Schreuder; B de Boer; R Dijkema; J Mulders; H J Theunissen; P D Grootenhuis; W G Hol
Journal:  Nat Struct Biol       Date:  1994-01

10.  Prostate-specific antigen in milk of lactating women.

Authors:  H Yu; E P Diamandis
Journal:  Clin Chem       Date:  1995-01       Impact factor: 8.327

View more
  5 in total

1.  The crystal structure of the mouse glandular kallikrein-13 (prorenin converting enzyme).

Authors:  D E Timm
Journal:  Protein Sci       Date:  1997-07       Impact factor: 6.725

2.  A theoretical model for the Gla-TSR-EGF-1 region of the anticoagulant cofactor protein S: from biostructural pathology to species-specific cofactor activity.

Authors:  B O Villoutreix; O Teleman; B Dahlbäck
Journal:  J Comput Aided Mol Des       Date:  1997-05       Impact factor: 3.686

3.  Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling.

Authors:  T Piironen; B O Villoutreix; C Becker; K Hollingsworth; M Vihinen; D Bridon; X Qiu; J Rapp; B Dowell; T Lövgren; K Pettersson; H Lilja
Journal:  Protein Sci       Date:  1998-02       Impact factor: 6.725

4.  A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy.

Authors:  Tracy R Daniels-Wells; Gustavo Helguera; Richard K Leuchter; Rafaela Quintero; Maggie Kozman; José A Rodríguez; Elizabeth Ortiz-Sánchez; Otoniel Martínez-Maza; Birgit C Schultes; Christopher F Nicodemus; Manuel L Penichet
Journal:  BMC Cancer       Date:  2013-04-17       Impact factor: 4.430

5.  Signal Enhancement in Oriented Immunosorbent Assays: A Balance between Accessibility of Antigen Binding Sites and Avidity.

Authors:  Vanessa Susini; Vanna Fierabracci; Gaia Barria; Lisa Dodoli; Laura Caponi; Aldo Paolicchi; Maria Franzini
Journal:  Biosensors (Basel)       Date:  2021-12-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.